Pascal Biosciences acquires STC technology for B-cell precursor ALL treatment

Canadian drug discovery and development company Pascal Biosciences has executed an exclusive, worldwide licence option agreement with STC.UNM (STC) to purchase a therapeutic monoclonal antibody for B-cell precursor acute lymphoblastic leukaemia (BCP- …
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news